Check back often to find the latest news on AgeneBio and our pipeline of multiple candidates.
December 21, 2015
The faces of Alzheimer’s Part IV: Face of the researcher and the future
Promising early research by John Hopkins University and startup drug company AgeneBio successfully showed low dose treatment of AGB101 to lab animals, like rats, resulted in calmed over-activity in the brain and improved memory performance in subjects experiencing memory loss and considered pre-dementia.
